Gαi-1/GNAI1 Antibody [B24D21] | Primary Antibodies

Application: Reactivity: Human, Mouse, Rat

Usage Information

Dilution
WB1:100-1:1000 IP1:100-1:200 IHC1:50-1:500 IF1:50-1:500

Application
WB, IP, IHC, IF

Reactivity
Human, Mouse, Rat

Source
Mouse Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
40 kDa 41 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
Gαi-1/GNAI1 Antibody [B24D21] detects endogenous levels of total Gαi-1/GNAI1 protein.

Clone
B24D21

Synonym(s)
Guanine nucleotide-binding protein G(i) subunit alpha-1, Adenylate cyclase-inhibiting G alpha protein, GNAI1

Background
Gαi‑1, encoded by GNAI1, is an inhibitory G protein α subunit of the Gi/o family that functions as a central transducer downstream of numerous G protein–coupled receptors (GPCRs), including receptors for biogenic amines, chemokines, and peptide hormones, and transmits ligand binding at the plasma membrane into coordinated changes in second messengers, ion fluxes, and cytoskeletal organization. The protein contains a conserved GTP‑binding pocket and switch regions typical of Gα subunits and cycles between an inactive GDP‑bound form tightly associated with Gβγ and an active GTP‑bound form released from Gβγ; GPCR activation promotes GDP release and GTP loading on Gαi‑1, while intrinsic and regulator of G protein signaling (RGS)–stimulated GTPase activity returns Gαi‑1 to the GDP‑bound state and terminates signaling. Active Gαi‑1 directly inhibits specific adenylyl cyclase isoforms, notably ADCY1, ADCY5, and ADCY6, which decreases conversion of ATP to cyclic AMP and reduces downstream cAMP‑dependent protein kinase (PKA) activity, thereby modulating phosphorylation programs that control secretion, contractility, metabolism, and gene expression. In parallel, freed Gβγ subunits released from Gi complexes activate effectors including G protein–gated inwardly rectifying K⁺ channels, voltage‑gated Ca²⁺ channels, phosphoinositide‑3‑kinase isoforms, and components of small GTPase pathways, positioning Gαi‑1–containing heterotrimers as central regulators of membrane excitability, chemotaxis, and survival pathways. Gαi‑1 also participates in non‑canonical mechanisms, including direct interactions with scaffold and signaling proteins beyond classical GPCR–effector axes, and contributes to actin cytoskeleton reorganization, cell migration, and proliferation, acting in concert with other Gα families in complex signaling networks. In growth factor signaling, Gαi‑family members form complexes with EGFR and the adaptor Gab1 and are required for full activation of the PI3K–Akt–mTORC1 pathway in response to epidermal growth factor, linking Gαi‑1 activity to control of protein synthesis, growth, and survival. Gαi‑1 is expressed broadly and is enriched in nervous system and endocrine tissues where GPCR control of neurotransmitter release, hormone secretion, and autonomic tone depends on Gi‑mediated suppression of cAMP and regulation of ion channels and exocytic machinery. Pathogenic GNAI1 variants are associated with a neurodevelopmental disorder characterized by hypotonia, impaired speech, and behavioral abnormalities, consistent with the importance of precise Gi‑dependent signaling during brain development, and bacterial toxins that deamidate Gαi‑family subunits lock them in an active state, altering RhoA signaling and contributing to infectious pathophysiology.

Background

Gαi‑1, encoded by GNAI1, is an inhibitory G protein α subunit of the Gi/o family that functions as a central transducer downstream of numerous G protein–coupled receptors (GPCRs), including receptors for biogenic amines, chemokines, and peptide hormones, and transmits ligand binding at the plasma membrane into coordinated changes in second messengers, ion fluxes, and cytoskeletal organization. The protein contains a conserved GTP‑binding pocket and switch regions typical of Gα subunits and cycles between an inactive GDP‑bound form tightly associated with Gβγ and an active GTP‑bound form released from Gβγ; GPCR activation promotes GDP release and GTP loading on Gαi‑1, while intrinsic and regulator of G protein signaling (RGS)–stimulated GTPase activity returns Gαi‑1 to the GDP‑bound state and terminates signaling. Active Gαi‑1 directly inhibits specific adenylyl cyclase isoforms, notably ADCY1, ADCY5, and ADCY6, which decreases conversion of ATP to cyclic AMP and reduces downstream cAMP‑dependent protein kinase (PKA) activity, thereby modulating phosphorylation programs that control secretion, contractility, metabolism, and gene expression. In parallel, freed Gβγ subunits released from Gi complexes activate effectors including G protein–gated inwardly rectifying K⁺ channels, voltage‑gated Ca²⁺ channels, phosphoinositide‑3‑kinase isoforms, and components of small GTPase pathways, positioning Gαi‑1–containing heterotrimers as central regulators of membrane excitability, chemotaxis, and survival pathways. Gαi‑1 also participates in non‑canonical mechanisms, including direct interactions with scaffold and signaling proteins beyond classical GPCR–effector axes, and contributes to actin cytoskeleton reorganization, cell migration, and proliferation, acting in concert with other Gα families in complex signaling networks. In growth factor signaling, Gαi‑family members form complexes with EGFR and the adaptor Gab1 and are required for full activation of the PI3K–Akt–mTORC1 pathway in response to epidermal growth factor, linking Gαi‑1 activity to control of protein synthesis, growth, and survival. Gαi‑1 is expressed broadly and is enriched in nervous system and endocrine tissues where GPCR control of neurotransmitter release, hormone secretion, and autonomic tone depends on Gi‑mediated suppression of cAMP and regulation of ion channels and exocytic machinery. Pathogenic GNAI1 variants are associated with a neurodevelopmental disorder characterized by hypotonia, impaired speech, and behavioral abnormalities, consistent with the importance of precise Gi‑dependent signaling during brain development, and bacterial toxins that deamidate Gαi‑family subunits lock them in an active state, altering RhoA signaling and contributing to infectious pathophysiology.

References
https://pubmed.ncbi.nlm.nih.gov/36092739/ pmc.ncbi.nlm.nih.gov/articles/PMC8107131/

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%